Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.

AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.

Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its headquarters campus in North Chicago. Construction is set to begin in spring 2026, ...

AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufactur | The ...

AbbVie is investing $380 million to build two new active pharmaceutical ingredient (API) manufacturing facilities at its ...

ByteDance's viral video generation model Seedance 2.0 was closely integrated with the Spring Festival gala's programming on Monday night China's "big tech" giants - including Alibaba Group Holding, ...

Will Zalatoris is rehabbing his mind, body and game after two back surgeries. The 29-year-old was a breakout star on the PGA ...

AbbVie invests $380m in North Chicago for API manufacturing, creating 300 jobs, boosting US R&D, and expanding domestic ...

Spring Modulith supports the development of functionally modularized Spring Boot applications. With Spring Modulith, it is possible to divide Spring Boot applications into functional modules with ...

Drilling permits issued by the Texas Railroad Commission, the state's oil and gas industry regulator.